Conditions: Multiple Myeloma
Keywords: Multiple Myeloma Revlimid
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 70
Healthy volunteers: no

Brief summary:
The purpose of this study to explore the combination of Revlimid®, oral cyclophosphamide and prednisone (RCP) in patients with newly diagnosed multiple myeloma.

Detailed description:
This is a phase II single institution trial in patients with newly diagnosed multiple myeloma. Revlimid® 25 mg p.o. daily on days 1-21 of each 28-day cycle. Cyclophosphamide 50 mg p.o. BID daily on days 1-21 of each 28-day cycle. Prednisone 50 mg p.o. Q.O.D..

Arms:
arm 1: Lenalidomide orally on Days 1-21 followed by 7 days rest, repeated every 28 days.

Cyclophosphamide twice daily, orally on Days 1-21 followed by 7 days rest, repeated every 28 days.

Prednisone every other day orally.

Interventions: intervention 1: lenalidomide (Revlimid®) intervention 2: Cyclophosphamide intervention 3: Prednisone
Intervention descriptions: intervention 1: 25 mg p.o. daily on days 1-21 of each 28 day cycle intervention 2: 50 mg p.o. BID daily on days 1-21 of each 28 day cycle intervention 3: 50 mg p.o. Q.O.D.

Protocol document: